Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) becomes gradually the most frequent liver disease in the world. Expert teams in the USA, Western Europe, and Russia give pride of place within the NAFLD treatment regime to lifestyle modification including the optimization of physical activity, diet and, as...

Full description

Saved in:
Bibliographic Details
Published inMedical Council no. 3; pp. 54 - 59
Main Authors Dicheva, D. T., Kuznetsova, E. I., Baeva, T. A.
Format Journal Article
LanguageEnglish
Russian
Published Remedium Group LLC 20.04.2018
Subjects
non-alcoholic fatty liver disease
ursodeoxycholic acid
Online AccessGet full text

Cover

More Information
Summary:Non-alcoholic fatty liver disease (NAFLD) becomes gradually the most frequent liver disease in the world. Expert teams in the USA, Western Europe, and Russia give pride of place within the NAFLD treatment regime to lifestyle modification including the optimization of physical activity, diet and, as a consequence, the BMI reduction. However, it is often difficult for the practitioner to motivate the patients to change their lifestyle and eating habits. Due to this, it is extremely important to use a pharmacologic therapy aimed at weight loss, reducing insulin resistance and repopulating the severely damaged liver parenchyma. By now ursodeoxycholic acid drugs (Ursosan) have been proved to be highly effective in treating NAFLD in clinical practice, having a significant impact on several pathogenetic mechanisms of this disease.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2018-3-54-59